NasdaqGS:ACADBiotechs
How FDA Fast Track For Remlifanserin In Alzheimer’s Psychosis At ACADIA (ACAD) Has Changed Its Investment Story
Earlier in July 2026, ACADIA Pharmaceuticals announced that the FDA granted Fast Track designation to remlifanserin, its investigational 5-HT2A inverse agonist for hallucinations and delusions in Alzheimer’s disease psychosis, alongside progress updates on the seamless Phase 2/3 RADIANT program.
This designation, coupled with ongoing Phase 3 enrollment, highlights how remlifanserin could meaningfully expand ACADIA’s late-stage CNS portfolio beyond its current commercial drugs.
Next, we’ll...